➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Patent: 10,383,357

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,383,357
Title:Selective reduction of tobacco-specific nitrosamines and related methods
Abstract: Aspects of the present disclosure relate to electrochemical reduction of tobacco-specific nitrosamines (TSNAs). According to certain methods described herein, a tobacco composition containing one or more TSNAs and nicotine is contacted with a solvent to form a tobacco mixture. In some embodiments, the tobacco mixture is introduced into an electrochemical device comprising an anode and a cathode. The tobacco mixture may, in some cases, form at least part of an initial electrolyte mixture that is in physical contact with at least a portion of the anode and at least a portion of the cathode. In some instances, an electrical potential is applied between the anode and the cathode, thereby reducing one or more TSNAs in the initial electrolyte mixture and producing a reduced electrolyte mixture. In certain cases, application of the electrical potential between the anode and the cathode does not cause non-TSNA components of the tobacco mixture (e.g., nicotine) to undergo electrochemical reduction or any other chemical reaction.
Inventor(s): Bromberg; Lev E. (Salem, MA), Su; Xiao (Cambridge, MA), Hatton; Trevor Alan (Sudbury, MA)
Assignee: Massachusetts Institute of Technology (Cambridge, MA)
Application Number:15/592,160
Patent Claims:see list of patent claims

Details for Patent 10,383,357

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Recordati Rare Diseases, Inc. PANHEMATIN hemin POWDER, FOR SOLUTION 101246 1 1983-07-20   Start Trial Massachusetts Institute of Technology (Cambridge, MA) 2036-05-10 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.